Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy (Q37798175)

23 August 2017

title

Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy (English)

1 reference

23 August 2017

1 reference

1 reference

1 reference

4

Masashi Mizokami

1 reference

23 August 2017

2

Yasuhito Tanaka

1 reference

23 August 2017

3

Ryuzo Ueda

1 reference

23 August 2017

1

Shigeru Kusumoto

1 reference

23 August 2017

publication date

6 October 2010

1 reference

Journal of Gastroenterology

23 August 2017

published in

1 reference

23 August 2017

volume

46

1 reference

23 August 2017

issue

1

1 reference

23 August 2017

page(s)

9-16

1 reference

Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Progressive multifocal leukoencephalopathy in a patient with B-cell lymphoma during rituximab-containing chemotherapy: case report and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Hepatitis B Virus Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Comprehensive analysis of risk factors associating with Hepatitis B virus (HBV) reactivation in cancer patients undergoing cytotoxic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

High hepatitis B virus (HBV) DNA viral load as the most important risk factor for HBV reactivation in patients positive for HBV surface antigen undergoing autologous hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Reverse seroconversion of hepatitis B after allogeneic bone marrow transplantation: a retrospective study of 37 patients with pretransplant anti-HBs and anti-HBc

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Hepatitis reactivation and liver failure in haemopoietic stem cell transplants for hepatitis B virus (HBV)/hepatitis C virus (HCV) positive recipients: a retrospective study by the Italian group for blood and marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Hepatic events after bone marrow transplantation in patients with hepatitis B infection: a case controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Measurement of hepatitis B virus core-related antigen as predicting factor for relapse after cessation of lamivudine therapy for chronic hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Reactivation of hepatitis B virus in HBsAg-negative patients with multiple myeloma: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Geographical and genetic diversity of the human hepatitis B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Classifying hepatitis B virus genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

A case-control study for differences among hepatitis B virus infections of genotypes A (subtypes Aa and Ae) and D.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Influence of genotypes and precore mutations on fulminant or chronic outcome of acute hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Hepatitis B virus reactivation in a surface antigen-negative and antibody-positive patient after rituximab plus CHOP chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Hepatitis B virus reactivation in a patient with chronic GVHD after allogeneic peripheral blood stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

High risk of hepatitis B-virus reactivation after hematopoietic cell transplantation in hepatitis B core antibody-positive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Reverse seroconversion of hepatitis B virus after allogeneic hematopoietic stem cell transplantation in the absence of chronic graft-versus-host disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Retrospective and prospective studies of hepatitis B virus reactivation in malignant lymphoma with occult HBV carrier

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Association between hepatitis B virus and pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Management of hepatitis B virus reactivation in patients with hematological malignancies treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Low incidence of hepatitis B virus reactivation during chemotherapy among diffuse large B-cell lymphoma patients who are HBsAg-negative/ HBcAb-positive: a multicenter retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Chronic hepatitis B: update 2009

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Adalimumab-induced lethal hepatitis B virus reactivation in an HBsAg-negative patient with clinically resolved hepatitis B virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Relevance of HBV/HBcAb screening in lymphoma patients treated in the Rituximab era

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-010-0331-4

Fatal HBV reactivation in a subject with anti-HBs and anti-HBc

21 January 2018

1 reference

12 December 2020

Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study.

1 reference

12 December 2020

Clinical and virological factors associated with hepatitis B virus reactivation in HBsAg-negative and anti-HBc antibodies-positive patients undergoing chemotherapy and/or autologous stem cell transplantation for cancer

1 reference

12 December 2020

Hepatitis B virus reactivation and role of antiviral prophylaxis in lymphoma patients with past hepatitis B virus infection who are receiving chemoimmunotherapy

1 reference

12 December 2020

Adjuvant rituximab causes prolonged hypogammaglobulinaemia following autologous stem cell transplant for non-Hodgkin's lymphoma

1 reference

12 December 2020

Maintenance rituximab after autologous stem cell transplant for high-risk B-cell lymphoma induces prolonged and severe hypogammaglobulinemia

1 reference

12 December 2020

Hepatitis B virus reactivation in adjuvant chemotherapy for breast cancer

1 reference

12 December 2020

Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy

1 reference

12 December 2020

Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab

1 reference

12 December 2020

Recommendations for identification and public health management of persons with chronic hepatitis B virus infection

1 reference

12 December 2020

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

12 December 2020

Neutropenia in patients treated with rituximab

1 reference

12 December 2020

10.1007/S00535-010-0331-4

Identifiers

DOI

1 reference

23 August 2017

1 reference